ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,328 GBX | -1.82% |
|
-0.56% | +16.30% |
| 12:39pm | US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug | RE |
| 06-26 | European Equities Close Lower in Wednesday Trading | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-07-25
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
158.5
USD
Average target price
174.4
USD
Spread / Average Target
+10.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.30% | 246B | |
| +55.17% | 811B | |
| +43.62% | 640B | |
| -7.05% | 353B | |
| +18.13% | 333B | |
| +8.76% | 302B | |
| +2.41% | 225B | |
| +12.47% | 218B | |
| +8.53% | 168B | |
| -3.68% | 155B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- Goldman Sachs Kicks Off AstraZeneca Coverage at Buy
